Dendreon Corporation is developing novel immunotherapies to treat cancer. It has one product, Provenge, approved for late-stage prostate cancer which works by re-engaging the immune system. While showing promise, Provenge faces challenges of high costs, lengthy approval delays, and lawsuits seeking earlier access. Dendreon needs to diversify its pipeline and pursue financing to support clinical trials and market expansion.
22. Financial Analysis (Fundamentals) For the last four years Dendreon has been consistently loosing money from $ 86.46 Million in 2005 to $ 70.48 Million in 2008. Revenues 2008 2007 2006 2005 (In Million) Revenue 0.11 100.0% 0.74 100.0% 0.27 100.0% 0.21 100.0% Other Revenue 0 0.0% 0 0.0% 0 0.0% 0 0.0% Total Revenue 0.11 100.00% 0.74 100.00% 0.27 100.00% 0.21 100.00% Income Statement 2008 2007 2006 2005 (In Million) Total operating Revenue 0.11 52.4% 0.74 352.4% 0.27 128.6% 0.21 100.0% Total Costs and Expenses 70.59 81.4% 102.36 118.1% 97.63 112.6% 86.67 100.0% Net Income -70.48 81.5% -101.62 117.5% -97.36 112.6% -86.46 100.0%
![Biotech Industry Analysis ,[object Object],[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)